HPV Diagnostics, Condom Labeling Will Be Focus Of Jan. 28 House Hearing
This article was originally published in The Gray Sheet
Executive Summary
FDA and the National Cancer Institute are among federal agencies asked to testify on cervical cancer prevention and research at a Jan. 28 hearing of the House Government Reform/Human Resources Subcommittee
You may also be interested in...
HPV and condom labeling
House Government Reform/Human Resources Subcommittee hearing Jan. 28 on human papillomavirus and the "best strategies" to prevent HPV infection postponed until Feb. 5 (1"The Gray Sheet" Jan.12, 2004, p. 17). The National Cancer Institute had been asked to testify on HPV and cervical cancer vaccine research, diagnostic technologies, treatment options, consequences and prevention strategies by Subcommittee Chair Mark Souder (R-Ind.). Also asked to testify were the heads of CDC, FDA and CMS...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”